PDF herunterladen
Semin Neurol 2005; 25(2): 185-195
DOI: 10.1055/s-2005-871327
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Evaluation and Treatment of Painful Peripheral Polyneuropathy

J. Robinson Singleton1
  • 1Department of Neurology, University of Utah, Salt Lake City, Utah
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. Juni 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Pain is a common component of sensory peripheral polyneuropathy and occurs primarily as a consequence of injury to small, unmyelinated C-fiber nerve axons. This class of fibers is particularly vulnerable to metabolic injury, and the neuropathy manifests in a length-dependent pattern. Diabetes mellitus, prediabetes associated with insulin resistance, toxins, and drugs are common causes of painful neuropathy, but a substantial percentage are idiopathic. Pathogenesis of neuropathic pain involves loss of peripheral axons and inappropriate peripheral and central adaptation of neuronal signaling to this loss. Treatment of painful neuropathy should be directed at removing the offending metabolic injury, if possible. Antiepileptic drugs, tricyclic antidepressants, opiates, and other treatments have shown efficacy in clinical trials for symptomatic relief of neuropathic pain.

KEYWORDS

Allodynia - diabetes - evaluation - intraepidermal nerve fiber counting (IENF) - human immunodeficiency virus (HIV) - hyperalgesia - nerve conduction studies (NCS) - neuropathic pain - paresthesia - polyneuropathy - quantitative sudomotor axon reflex testing (QSART) - treatment

REFERENCES

  • 1 Dyck P J, Oviatt K F, Lambert E H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis.  Ann Neurol. 1981;  10 222-226
    CrossrefPubMedGoogle Scholar
  • 2 Low P A. Autonomic nervous system function.  J Clin Neurophysiol. 1993;  10 14-27
    PubMedGoogle Scholar
  • 3 Novak V, Freimer M L, Kissel J T et al.. Autonomic impairment in painful neuropathy.  Neurology. 2001;  56 861-868
    PubMedGoogle Scholar
  • 4 Dyck P J, Grant I A, Fealey R D. Ten steps in characterizing and diagnosing patients with peripheral neuropathy.  Neurology. 1996;  47 10-17
    PubMedGoogle Scholar
  • 5 Periquet M I, Novak V, Collins M P et al.. Painful sensory neuropathy: prospective evaluation using skin biopsy.  Neurology. 1999;  53 1641-1647
    CrossrefPubMedGoogle Scholar
  • 6 Smith A G, Singleton J R. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy.  Arch Intern Med. 2004;  164 1021-1025
    CrossrefPubMedGoogle Scholar
  • 7 Singleton J R, Smith A G, Bromberg M B. Painful sensory neuropathy associated with impaired glucose tolerance.  Muscle Nerve. 2001;  24 1225-1228
    CrossrefPubMedGoogle Scholar
  • 8 Singleton J R, Smith A G, Bromberg M B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.  Diabetes Care. 2001;  24 1448-1453
    CrossrefPubMedGoogle Scholar
  • 9 Periquet M I, Novak V, Collins M P et al.. Painful sensory neuropathy: prospective evaluation using skin biopsy.  Neurology. 1999;  53 1641-1647
    CrossrefPubMedGoogle Scholar
  • 10 Smith A G, Tripp C, Singleton J R. Skin biopsy findings in patients with neuropathy associated with diabetes and impaired glucose tolerance.  Neurology. 2001;  57 1701-1704
    CrossrefPubMedGoogle Scholar
  • 11 Holland N R, Stocks A, Hauer P, Cornblath D R, Griffin J W, McArthur J C. Intraepidermal nerve fiber density in patients with painful sensory neuropathy.  Neurology. 1997;  48 708-711
    CrossrefPubMedGoogle Scholar
  • 12 Herrmann D, Griffin J, Hauer P, Cornblath D R, McArthur J C. Epidermal nerve fiber density: association with sural nerve morphometry and electrophysiology in peripheral neuropathies.  Neurology. 1999;  52(suppl 2) A309-A310
    PubMedGoogle Scholar
  • 13 Low P A, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease.  Muscle Nerve. 2003;  27 646-661
    CrossrefPubMedGoogle Scholar
  • 14 Holland N R, Crawford T O, Hauer P, Cornblath D R, Griffin J W, McArthur J C. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases.  Ann Neurol. 1998;  44 47-59
    CrossrefPubMedGoogle Scholar
  • 15 Freeman R, Chase K P, Risk M R. Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy.  Neurology. 2003;  60 465-470
    PubMedGoogle Scholar
  • 16 Kang P B, Hoffman S N, Krimitsos E, Rutkove S B. Ambulatory foot temperature measurement: a new technique in polyneuropathy evaluation.  Muscle Nerve. 2003;  27 737-742
    PubMedGoogle Scholar
  • 17 Woolf C J. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy.  Life Sci. 2004;  74 2605-2610
    CrossrefPubMedGoogle Scholar
  • 18 Spruce M C, Potter J, Coppini D V. The pathogenesis and management of painful diabetic neuropathy: a review.  Diabet Med. 2003;  20 88-98
    CrossrefPubMedGoogle Scholar
  • 19 Woolf C J, Mannion R J. Neuropathic pain: aetiology, symptoms, mechanisms, and management.  Lancet. 1999;  353 1959-1964
    CrossrefPubMedGoogle Scholar
  • 20 Waxman S G, Cummins T R, Dib-Hajj S D, Black J A. Voltage-gated sodium channels and the molecular pathogenesis of pain: a review.  J Rehabil Res Dev. 2000;  37 517-528
    PubMedGoogle Scholar
  • 21 Cummins T R, Dib-Hajj S D, Waxman S G. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.  J Neurosci. 2004;  24 8232-8236
    CrossrefPubMedGoogle Scholar
  • 22 Woolf C J, Salter M W. Neuronal plasticity: increasing the gain in pain.  Science. 2000;  288 1765-1768
    CrossrefPubMedGoogle Scholar
  • 23 Noguchi K, Kawai Y, Fukuoka T, Senba E, Miki K. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons.  J Neurosci. 1995;  15 7633-7643
    PubMedGoogle Scholar
  • 24 Moore K A, Kohno T, Karchewski L A, Scholz J, Baba H, Woolf C J. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.  J Neurosci. 2002;  22 6724-6731
    PubMedGoogle Scholar
  • 25 Keay K A, Monassi C R, Levison D B, Bandler R. Peripheral nerve injury evokes disabilities and sensory dysfunction in a subpopulation of rats: a closer model to human chronic neuropathic pain?.  Neurosci Lett. 2004;  361 188-191
    CrossrefPubMedGoogle Scholar
  • 26 Dyck P J, Kratz J M, Karnes J L et al.. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.  Neurology. 1993;  43 817-824
    CrossrefPubMedGoogle Scholar
  • 27 Ziegler D, Gries F A, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy.  J Diabetes Complications. 1992;  6 49-57
    CrossrefPubMedGoogle Scholar
  • 28 Said G, Elgrably F, Lacroix C et al.. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome.  Ann Neurol. 1997;  41 762-770
    CrossrefPubMedGoogle Scholar
  • 29 Pascoe M K, Low P A, Windebank A J, Litchy W J. Subacute diabetic proximal neuropathy.  Mayo Clin Proc. 1997;  72 1123-1132
    CrossrefPubMedGoogle Scholar
  • 30 Lehtinen J M, Uusitupa M, Siitonen O, Pyorala K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects.  Diabetes. 1989;  38 1307-1313
    PubMedGoogle Scholar
  • 31 Cohen J A, Jeffers B W, Faldut D, Marcoux M, Schrier R W. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependent diabetes mellitus (NIDDM).  Muscle Nerve. 1998;  21 72-80
    CrossrefPubMedGoogle Scholar
  • 32 Novella S P, Inzucchi S E, Goldstein J M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy.  Muscle Nerve. 2001;  24 1229-1231
    CrossrefPubMedGoogle Scholar
  • 33 Sumner C J, Sheth S, Griffin J W, Cornblath D R, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance.  Neurology. 2003;  60 108-111
    CrossrefPubMedGoogle Scholar
  • 34 Diabetes Control and Complications Trial Research Group . Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial.  Ann Neurol. 1995;  38 869-880
    CrossrefPubMedGoogle Scholar
  • 35 Diabetes Control and Complications Trial Research Group . The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.  Diabetes. 1996;  45 1289-1298
    CrossrefPubMedGoogle Scholar
  • 36 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
    CrossrefPubMedGoogle Scholar
  • 37 Tuomilehto J, Lindstrom J, Eriksson J G et al.. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    CrossrefPubMedGoogle Scholar
  • 38 Perry R C, Baron A D. Impaired glucose tolerance: why is it not a disease?.  Diabetes Care. 1999;  22 883-885
    PubMedGoogle Scholar
  • 39 Polydefkis M, Yiannoutsos C T, Cohen B A et al.. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.  Neurology. 2002;  58 115-119
    CrossrefPubMedGoogle Scholar
  • 40 Hahn K, Arendt G, Braun J S et al.. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.  J Neurol. 2004;  251 1260-1266
    CrossrefPubMedGoogle Scholar
  • 41 Simpson D M, McArthur J C, Olney R et al.. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.  Neurology. 2003;  60 1508-1514
    PubMedGoogle Scholar
  • 42 Adams D. Hereditary and acquired amyloid neuropathies.  J Neurol. 2001;  248 647-657
    CrossrefPubMedGoogle Scholar
  • 43 Comenzo R L. Primary systemic amyloidosis.  Curr Treat Options Oncol. 2000;  1 83-89
    PubMedGoogle Scholar
  • 44 van de Poel M H, Coebergh J W, Hillen H F. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands.  Br J Haematol. 1995;  91 121-125
    PubMedGoogle Scholar
  • 45 Orstavik K, Mork C, Kvernebo K, Jorum E. Pain in primary erythromelalgia: a neuropathic component?.  Pain. 2004;  110 531-538
    CrossrefPubMedGoogle Scholar
  • 46 Schiffmann R, Floeter M K, Dambrosia J M et al.. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.  Muscle Nerve. 2003;  28 703-710
    CrossrefPubMedGoogle Scholar
  • 47 Hilz M J, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.  Neurology. 2004;  62 1066-1072
    PubMedGoogle Scholar
  • 48 Sinha S, Mahadevan A, Lokesh L et al.. Tangier disease-a diagnostic challenge in countries endemic for leprosy.  J Neurol Neurosurg Psychiatry. 2004;  75 301-304
    CrossrefPubMedGoogle Scholar
  • 49 Chin R L, Sander H W, Brannagan T H et al.. Celiac neuropathy.  Neurology. 2003;  60 1581-1585
    CrossrefPubMedGoogle Scholar
  • 50 Cicarelli G, Della Rocca G, Amboni M et al.. Clinical and neurological abnormalities in adult celiac disease.  Neurol Sci. 2003;  24 311-317
    CrossrefPubMedGoogle Scholar
  • 51 Windebank A J. Chemotherapeutic neuropathy.  Curr Opin Neurol. 1999;  12 565-571
    CrossrefPubMedGoogle Scholar
  • 52 Abernathy C O, Liu Y P, Longfellow D et al.. Arsenic: health effects, mechanisms of actions, and research issues.  Environ Health Perspect. 1999;  107 593-597
    PubMedGoogle Scholar
  • 53 Moeschlin S. Thallium poisoning.  Clin Toxicol. 1980;  17 133-146
    CrossrefPubMedGoogle Scholar
  • 54 Schaumburg H H, Berger A. Alopecia and sensory polyneuropathy from thallium in a Chinese herbal medication.  JAMA. 1992;  268 3430-3431
    CrossrefPubMedGoogle Scholar
  • 55 Verstappen C C, Heimans J J, Hoekman K, Postma T J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.  Drugs. 2003;  63 1549-1563
    PubMedGoogle Scholar
  • 56 Paulson O B, Melgaard B, Hansen H S et al.. Misonidazole neuropathy.  Acta Neurol Scand Suppl. 1984;  100 133-136
    PubMedGoogle Scholar
  • 57 Blum A S, Dal Pan G J, Feinberg J et al.. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors.  Neurology. 1996;  46 999-1003
    PubMedGoogle Scholar
  • 58 Parry G J, Bredesen D E. Sensory neuropathy with low dose pyridoxine.  Neurology. 1985;  35 1466-1468
    PubMedGoogle Scholar
  • 59 Schaumburg H, Kaplan J, Windebank A et al.. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome.  N Engl J Med. 1983;  309 445-448
    CrossrefPubMedGoogle Scholar
  • 60 Hallett M, Fox J G, Rogers A E et al.. Controlled studies on the effects of alcohol ingestion on peripheral nerves of macaque monkeys.  J Neurol Sci. 1987;  80 65-71
    CrossrefPubMedGoogle Scholar
  • 61 Bosch E P, Pelham R W, Rasool C G et al.. Animal models of alcoholic neuropathy: morphologic, electrophysiologic, and biochemical findings.  Muscle Nerve. 1979;  2 133-144
    PubMedGoogle Scholar
  • 62 Monforte R, Estruch R, Valls-Sole J, Nicolas J, Villalta J, Urbano-Marquez A. Autonomic and peripheral neuropathies in patients with chronic alcoholism. A dose-related toxic effect of alcohol.  Arch Neurol. 1995;  52 45-51
    PubMedGoogle Scholar
  • 63 Gorson K C, Ropper A H. Idiopathic small fiber neuropathy.  Acta Neurol Scand. 1995;  92 376-382
    PubMedGoogle Scholar
  • 64 Sindrup S H, Jensen T S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.  Pain. 1999;  83 389-400
    CrossrefPubMedGoogle Scholar
  • 65 Namaka M, Gramlich C R, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain.  Clin Ther. 2004;  26 951-979
    CrossrefPubMedGoogle Scholar
  • 66 Max M B, Culnane M, Schafer S C et al.. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.  Neurology. 1987;  37 589-596
    PubMedGoogle Scholar
  • 67 Max M B, Lunch S A, Muir J, Shoaf S E, Smoller B, Dubner R. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy.  N Engl J Med. 1992;  326 1250-1256
    CrossrefPubMedGoogle Scholar
  • 68 Morello C M, Leckband S G, Stoner C P, Moorhouse D F, Sahagian G A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.  Arch Intern Med. 1999;  159 1931-1937
    CrossrefPubMedGoogle Scholar
  • 69 Polydefkis M, Allen R P, Hauer P, Earley C J, Griffin J W, McArthur J C. Subclinical sensory neuropathy in late-onset restless legs syndrome.  Neurology. 2000;  55 1115-1121
    PubMedGoogle Scholar
  • 70 Backonja M M. Use of anticonvulsants for treatment of neuropathic pain.  Neurology. 2002;  59(suppl 2) S14-S17
    PubMedGoogle Scholar
  • 71 Backonja M, Beydoun A, Edwards K R et al.. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.  JAMA. 1998;  280 1831-1836
    CrossrefPubMedGoogle Scholar
  • 72 Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin.  Neurology. 2001;  57 1717-1719
    PubMedGoogle Scholar
  • 73 Fisher R S, Sachdeo R C, Pellock J, Penovich P E, Magnus L, Bernstein P. Rapid initiation of gabapentin: a randomized, controlled trial.  Neurology. 2001;  56 743-748
    PubMedGoogle Scholar
  • 74 Gomez-Perez F J, Choza R, Rios J M et al.. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.  Arch Med Res. 1996;  27 525-529
    PubMedGoogle Scholar
  • 75 Sindrup S H, Jensen T S. Pharmacotherapy for trigeminal neuralgia.  Clin J Pain. 2002;  18 22-27
    CrossrefPubMedGoogle Scholar
  • 76 Simpson D M, Olney R, McArthur J C, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy.  Neurology. 2000;  54 2115-2119
    PubMedGoogle Scholar
  • 77 Watson C P. The treatment of neuropathic pain: antidepressants and opioids.  Clin J Pain. 2000;  16(suppl 2) S49-S55
    CrossrefPubMedGoogle Scholar
  • 78 Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics.  Pain. 1994;  57 153-160
    CrossrefPubMedGoogle Scholar
  • 79 Martin T J, Hairston C T, Lutz P O, Harris L S, Porreca F. Anti-allodynic actions of intravenous opioids in the nerve injured rat: potential utility of heroin and dihydroetorphine against neuropathic pain.  Eur J Pharmacol. 1998;  357 25-32
    CrossrefPubMedGoogle Scholar
  • 80 Harati Y, Gooch C, Swenson M et al.. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy.  J Diabetes Complications. 2000;  14 65-70
    CrossrefPubMedGoogle Scholar
  • 81 Harati Y, Gooch C, Swenson M et al.. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.  Neurology. 1998;  50 1842-1846
    CrossrefPubMedGoogle Scholar
  • 82 Duhmke R M, Cornblath D D, Hollingshead J R. Tramadol for neuropathic pain.  Cochrane Database Syst Rev. 2004;  2 CD003726
    PubMedGoogle Scholar
  • 83 Jarvis B, Coukell A J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.  Drugs. 1998;  56 691-707
    CrossrefPubMedGoogle Scholar
  • 84 Forst T, Pohlmann T, Kunt T et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy.  Acta Diabetol. 2002;  39 1-6
    CrossrefPubMedGoogle Scholar
  • 85 Wolfe G I, Baker N S, Amato A A et al.. Chronic cryptogenic sensory polyneuropathy: clinical and abloratory characteristics.  Arch Neurol. 1999;  56 540-547
    CrossrefPubMedGoogle Scholar
  • 86 Wolfe G I, Barohn R J. Cryptogenic sensory and sensorimotor polyneuropathies.  Semin Neurol. 1998;  18 105-111
    PubMedGoogle Scholar
  • 87 Notermans N C, Wokke J H, Franssen H et al.. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study in 75 patients.  J Neurol Neurosurg Psychiatry. 1993;  56 1066-1071
    CrossrefPubMedGoogle Scholar
  • 88 Verghese J, Bieri P L, Gellido C, Schaumburg H H, Herskovitz S. Peripheral neuropathy in young-old and old-old patients.  Muscle Nerve. 2001;  24 1476-1481
    PubMedGoogle Scholar

J. Robinson SingletonM.D. 

Associate Professor, Department of Neurology, University of Utah

SOM 3R-152, 1900 E. 30 N., Salt Lake City, UT 84132

      >